Inclisiran

1. Inclisiran decreases LDL cholesterol in humans (-46% (-60.8 to -33.8%)).

   Humans3 years43.1% femalesn = 109

   Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network · Clinical research in cardiology : official journal of the German Cardiac Society · 28 Sep 2026

LDL cholesterol →

1. Inclisiran increases calcified plaque in humans (+10.60 mm 3 (6.60-14.60)).

   “calcified plaque increased from 56.5 mm 3 (45.6-67.3) to 67.1 mm 3 (55.9-78.2”

   Humans15 months

   Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study · Diagnostics (Basel, Switzerland) · 17 Sep 2026

1. Inclisiran decreases low-density non-calcified plaque in humans.

   “Low-density non-calcified plaque (LDNC) decreased from 27.3 mm 3 (23.1-31.6) to 22.7 mm 3 (18.0-27.4; overall p = 0.0035)”

   Humans15 months

   Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study · Diagnostics (Basel, Switzerland) · 17 Sep 2026

1. Inclisiran has no effect on total plaque volume in humans (p = 0.713).

   “No significant time effect was detected for the total plaque volume ( p = 0.713).”

   Humans15 months

   Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study · Diagnostics (Basel, Switzerland) · 17 Sep 2026

1. Inclisiran decreases low-density lipoprotein cholesterol in humans (117.4 to 45.9 mg/dL).

   “The LDL-C levels decreased from 117.4 mg/dL (95% confidence interval [CI], 113.3-121.6) to 45.9 mg/dL (39.5-52.3) at 15 months.”

   Humans15 months

   Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study · Diagnostics (Basel, Switzerland) · 17 Sep 2026

Low-density lipoprotein cholesterol →